John Vissing

Centre De Référence De Pathologie Neuromusculaire Paris Est
Estonia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 395 publications

Clinical, histopathological, and biomarker characterization of XLMTM and ADCNM: Operational lessons, screening and baseline data of the Unite-CNM study.

Clinical, histopathological, and biomarker characterization of XLMTM and ADCNM: Operational lessons, screening and baseline data of the Unite-CNM study.

Journal: Journal of neuromuscular diseases

Published: August 14, 2026

Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial.

Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial.

Journal: JAMA neurology

Published: August 10, 2026

Assisted leg cycle exercise for wheelchair users with muscular dystrophy.

Assisted leg cycle exercise for wheelchair users with muscular dystrophy.

Journal: Journal of neuromuscular diseases

Published: July 22, 2026

Myocardial fat fraction in Becker muscular dystrophy and women carrying pathogenic DMD gene variants assessed by Dixon cardiac MRI.

Myocardial fat fraction in Becker muscular dystrophy and women carrying pathogenic DMD gene variants assessed by Dixon cardiac MRI.

Journal: Journal of neuromuscular diseases

Published: July 21, 2026

Hospital resource utilization in patients with generalized myasthenia gravis treated with nipocalimab: results from the VIVACITY-MG3 study.

Hospital resource utilization in patients with generalized myasthenia gravis treated with nipocalimab: results from the VIVACITY-MG3 study.

Journal: Journal of medical economics

Published: July 20, 2026

Mitochondrial diseases

Mitochondrial diseases

Journal: Ugeskrift for laeger

Published: July 03, 2026

Prevalence and Disability of Peripheral Neuropathy in Patients With Waldenström's Macroglobulinemia.

Prevalence and Disability of Peripheral Neuropathy in Patients With Waldenström's Macroglobulinemia.

Journal: European journal of haematology

Published: June 29, 2026

In response to: Personalized antioxidant supplementation improves muscle strength, physical activity, and quality of life in patients with FSHD1: A real-world longitudinal study. Laoudj-Chenivesse D, Arbogast S, Raynaud De Mauverger E, Fedou C, Debroize E, Hugon G, Pincemail J, Picot MC, Cristol JP, Mercier J, Portet F. Free Radic Biol Med. 2026 Feb 28; 248: 424-435.

In response to: Personalized antioxidant supplementation improves muscle strength, physical activity, and quality of life in patients with FSHD1: A real-world longitudinal study. Laoudj-Chenivesse D, Arbogast S, Raynaud De Mauverger E, Fedou C, Debroize E, Hugon G, Pincemail J, Picot MC, Cristol JP, Mercier J, Portet F. Free Radic Biol Med. 2026 Feb 28; 248: 424-435.

Journal: Free radical biology & medicine

Published: April 26, 2026

Normative data and predictors of postural sway using static and dynamic balance tests in adults aged 20-69 years.

Normative data and predictors of postural sway using static and dynamic balance tests in adults aged 20-69 years.

Journal: Gait & posture

Published: March 20, 2026

Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.

Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: March 11, 2026

Prevalence and characteristics of patients with seronegative myasthenia gravis.

Prevalence and characteristics of patients with seronegative myasthenia gravis.

Journal: Journal of neurology

Published: March 11, 2026

Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).

Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).

Journal: Journal of neurology

Published: February 22, 2026

Showing 1-12 of 395

Last Updated: 09/26/2026